Baqi L, Payer J, Killinger Z, Hruzikova P, Cierny D, Susienkova K, Langer P
5th Clinic of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Endocr Regul. 2010 Apr;44(2):57-63. doi: 10.4149/endo_2010_02_57.
This cross-sectional study aimed to evaluate the interrelations between endogenous TSH level on one side and the status of bone mineral density (BMD) and bone metabolic turnover (BMT) on the other in pooled four groups of premenopausal women either without or with a long-term L-thyroxine treatment.
Serum levels of free thyroxine (FT4), thyrotropin (TSH), calcium (Ca), alkaline phosphatase (ALP), osteocalcin OC) and cross linked N-telopeptide of type 1 collagen (NTx) as well as urinary calcium (U-Ca/24h), bone mineral density of lumbar spine L 1-4 (BMD-L) and femoral hip (BMD-F) were estimated in a cohort of 151 premenopausal women (median 36 years) consisting of four groups: Group 1, 40 healthy untreated women, while three other groups consisted of patients previously treated for about 5 years; Group 2, 41 patients with genuine hypothyroidism treated by L-thyroxine (50-100 microg daily); Group 3, 40 patients with genuine hyperthyroidism treated by Carbimazol (10-15 mg daily); Group 4, 30 patients treated by suppressive doses of L-thyroxine (100-150 microg daily) after thyroidectomy for thyroid cancer (n=10) or because of progressively growing benign goitre (n=20).
When using multiple correlation analysis (Pearson's r) in pooled 151 women, TSH showed significant positive correlation with BMD-L (p<0.01) and BMD-F (p<0.001) and, at the same time, significant negative correlation with serum level of BMT markers such as ALP (p<0.05), OC (p<0.05) and NTx (p<0.01), while the correlation of FT4 with BMD-L, BMD-F was significantly negative (p<0.001 for both) and that with all BMT markers was significantly positive (p<0.05 to <0.001). Thus, it appeared that higher TSH level was associated with increased bone mineral density and, at the same, with decreased bone metabolic turnover. These interrelations were further supported by the findings of significantly lower BMD-F (p<0.01), BMD-L (p<0.001) and significantly higher ALP, OC and NTX (all at p<0.001) in the group of 36 women with TSH level<0.3 mU/l as compared to the group of 115 women with TSH level range of 0.35-6.3 mU/l).
Irrespectively of thyroid diagnosis and/or previous long term thyroxine treatment in some groups, this cross sectional study showed that, after the pooled group of 151 women has been redistributed according to the actual TSH level, the bone mineral density and the level of bone turnover markers was significantly more favorable in 115 subjects with TSH level range of 0.35-6.3 mU/l than these in 36 women with TSH<0.3 mU/l.
本横断面研究旨在评估四组合并的绝经前女性中,一方面内源性促甲状腺激素(TSH)水平与另一方面骨矿物质密度(BMD)状态和骨代谢转换(BMT)之间的相互关系,这些女性有无长期左甲状腺素治疗。
在151名绝经前女性(中位年龄36岁)队列中,估计血清游离甲状腺素(FT4)、促甲状腺激素(TSH)、钙(Ca)、碱性磷酸酶(ALP)、骨钙素(OC)和1型胶原交联N-端肽(NTx)水平以及尿钙(U-Ca/24h)、腰椎L1-4骨矿物质密度(BMD-L)和股骨颈骨矿物质密度(BMD-F)。该队列由四组组成:第1组,40名未接受治疗的健康女性,而其他三组由先前接受治疗约5年的患者组成;第2组,41名接受左甲状腺素治疗(每日50-100微克)的真性甲状腺功能减退患者;第3组,40名接受卡比马唑治疗(每日10-15毫克)的真性甲状腺功能亢进患者;第4组,30名因甲状腺癌(n=10)或因逐渐增大的良性甲状腺肿(n=20)行甲状腺切除术后接受抑制剂量左甲状腺素(每日100-150微克)治疗的患者。
在151名合并女性中采用多重相关分析(Pearson相关系数r)时,TSH与BMD-L(p<0.01)和BMD-F(p<0.00)呈显著正相关,同时与BMT标志物血清水平如ALP(p<0.05)、OC(p<0.05)和NTx(p<0.01)呈显著负相关,而FT4与BMD-L、BMD-F的相关性显著为负(两者均p<0.001),与所有BMT标志物的相关性显著为正(p<0.05至<0.001)。因此,似乎较高的TSH水平与骨矿物质密度增加相关,同时与骨代谢转换降低相关。与TSH水平范围为0.35-6.3 mU/l的115名女性组相比,TSH水平<0.3 mU/l的36名女性组中BMD-F(p<0.01)、BMD-L(p<0.001)显著降低,ALP、OC和NTX显著升高(均p<0.001),这些结果进一步支持了上述相互关系。
无论甲状腺诊断情况和/或某些组先前的长期甲状腺素治疗如何,本横断面研究表明,在根据实际TSH水平对151名女性合并组进行重新分组后,TSH水平范围为0.35-6.3 mU/l的115名受试者的骨矿物质密度和骨转换标志物水平明显优于TSH<0.3 mU/l的36名女性。